Somewhat Positive Press Coverage Somewhat Unlikely to Impact Celgene (CELG) Stock Price
Press coverage about Celgene (NASDAQ:CELG) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.5422746877876 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Celgene (CELG) Given Hold Rating at Cantor Fitzgerald (americanbankingnews.com)
- 3 Biotech Stocks to Buy for 2018 – Motley Fool (fool.com)
- Seminole Management Co., Inc. Buys Delta Air Lines Inc, Verizon Communications Inc, Celgene Corp, Sells Micron … – GuruFocus.com (gurufocus.com)
- Mechanics Bank Trust Department Buys Monsanto Co, iShares Nasdaq Biotechnology Index Fund, Nestle SA, Sells … – GuruFocus.com (gurufocus.com)
- Celgene Stock May Reward Bottom Fishers (finance.yahoo.com)
CELG has been the topic of a number of research analyst reports. BMO Capital Markets boosted their price objective on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the company a “hold” rating in a research report on Wednesday, January 17th. Oppenheimer restated a “buy” rating and set a $170.00 target price on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. Finally, Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus target price of $130.35.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 64.14%. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same period last year, the firm posted $1.61 EPS. The company’s revenue was up 16.9% on a year-over-year basis. equities analysts expect that Celgene will post 7.82 earnings per share for the current year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.